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doses).11 This adds weight to the argument of starting chela-
tion with deferasirox early in the course of MDS when lower










1Royal Bournemouth and Christchurch NHS Foundation Trust, 2Cancer
Research UK Clinical Trials Unit (CRCTU), University of Birming-
ham, Birmingham, 3Clinical Trials and Statistics Unit, The Institute of
Cancer Research, London, 4Nottingham University Hospitals NHS
Trust, Nottingham, 5Cardiovascular Magnetic Resonance (CMR) Unit,
Royal Brompton and Harefield NHS Foundation Trust, 6Research
Department of Haematology, University College London, London,
7St James’s University Hospital, Leeds Teaching Hospitals NHS Trust,
Leeds and 8Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK.
E-mail: dominic.culligan@nhs.net
First published online 27 April 2020
doi: 10.1111/bjh.16669
References
1. de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hell-
strom-Lindberg E, et al. Labile plasma iron levels predict survival in
patients with lower-risk myelodysplastic syndromes. Haematologica.
2018;103:69–79.
2. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E,
et al. Prognostic factors and life expectancy in myelodysplastic syndromes
classified according to WHO criteria: a basis for clinical decision making.
J Clin Oncol. 2005;23:7594–603.
3. Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler
A, et al. Deferasirox in iron-overloaded patients with transfusion-depen-
dent myelodysplastic syndromes: results from the large 1-year EPIC study.
Leuk Res. 2010;34:1143–50.
4. List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N,
et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC
transfusion-dependent patients with myelodysplastic syndrome. J Clin
Oncol. 2012;30:2134–9.
5. Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, et al.
Impact of treatment with iron chelation therapy in patients with lower-
risk myelodysplastic syndromes participating in the European MDS reg-
istry. Haematologica. 2020;105:640-51.
6. Wong CA, Leitch HA. Delayed time from RBC transfusion dependence to
first cardiac event in lower IPSS risk MDS patients receiving iron chelation
therapy. Leuk Res. 2019;83:106170.
7. Angelucci E, Li J, Greenberg PL, Depei W, Hou M, Figueroa E, et al.
Safety and efficacy, including event-free survival, of deferasirox versus pla-
cebo in iron-overloaded patients with low- and Int-1 myelodysplastic syn-
dromes: outcomes from the randomized, double-blind Telesto study.
Blood. 2018;132:234.
8. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW,
Nimer SD, et al. Clinical application and proposal for modification of the
International Working Group (IWG) response criteria in myelodysplasia.
Blood. 2006;108:419–25.
9. Lawless JF. Statistical Models and Methods for Lifetime data. New York:
John Wiley and Sons; 1982.
10. Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-
Bresler A, et al. Hematologic responses to deferasirox therapy in transfu-
sion-dependent patients with myelodysplastic syndromes. Haematologica.
2012;97:1364–71.
11. Meunier M, Ancelet S, Lefebvre C, Arnaud J, Garrel C, Pezet M, et al.
Reactive oxygen species levels control NF-kappaB activation by low dose
deferasirox in erythroid progenitors of low risk myelodysplastic syn-
dromes. Oncotarget. 2017;8:105510–24.
High-level induction of fetal haemoglobin by pomalidomide in
b-thalassaemia/HbE erythroid progenitor cells
Studies have shown that increased expression of fetal haemo-
globin (HbF; a2c2) can ameliorate red blood cell deficiencies
in patients with b-thalassaemia and sickle cell disease (SCD).1–3
Pharmacological induction of HbF expression in b-thalas-
saemia has been investigated using several classes of small
molecules,4 including 5-azacytidine,5 decitabine,6 hydrox-
yurea,7 LSD1 inhibitors (tranylcypromine and RN-1),8,9 and
short chain fatty acid derivatives.10,11 Among these molecules,
hydroxyurea is the only U.S. Food and Drug Administration
(FDA) currently approved drug for the treatment of SCD and/
or b-thalassaemia. However, hydroxyurea has shown modest
and variable responses with potential myelosuppression in b-
thalassaemia patients. Therefore, more robust and safer HbF
therapeutics are highly desired.
Pomalidomide, an FDA-approved immunomodulatory
drug for the treatment of multiple myeloma,12,13 stimulates
c-globin mRNA and HbF expression in erythroid progenitor
cells by downregulating factors involved in c-globin repres-
sion, including BCL11A, SOX6, GATA1, KLF1 and LSD1.14–16
In addition, treatment of a humanized mouse model of SCD
with pomalidomide induced comparable HbF expression to
hydroxyurea, but without myelosuppressive effects.15
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Here, we investigated the therapeutic potential of poma-
lidomide and its combined effects with other HbF inducers,
including hydroxyurea, decitabine and RN-1, in erythroid
progenitor cells from compound heterozygous b0-thalas-
saemia/HbE (HBB:c.79G>A) patients (Table SI) using a
three-phase liquid culture system that supports terminal mat-
uration of erythroid cells (Data S1 and Fig S1). Comparison
of results using optimal conditions for each compound (Figs
S2 and S3) revealed that pomalidomide was much more
effective in inducing HbF expression than hydroxyurea, deci-
tabine or RN-1 (Fig 1A,B). The greatest increase in HbF per-
centage from the baseline level was observed in
pomalidomide-treated cells, achieving 256  11% as deter-
mined by high-performance liquid chromatography (HPLC)
(Fig 1A,B). b0-thalassaemia/HbE precursors from patients of
different b0-thalassemic mutations (Table SI) showed simi-
larly increased levels of HbF induction in response to poma-
lidomide treatment. This result suggested that deficient
progenitors, regardless of specific b0-thalassemic mutation or
baseline HbF level, are all susceptible to strong induction
with pomalidomide (Fig 1A,B and Tables SI and SII). The
percentage of cells expressing HbF (F cells) increased from
498  47% for dimethyl sulfoxide (DMSO) controls to
606  25% after pomalidomide treatment (Fig S4). By
quantitative reverse transcription polymerase chain reaction
(RT-PCR), we found that pomalidomide significantly
increased c-globin (HBG) mRNA expression, achieving a
23  03-fold increase over control cells, with coincidentally
diminished b-globin (HBB) expression, without significant
change in a-globin (HBA) expression (Fig 1C).
To enhance the level of HbF induction, we investigated the
effects of combined treatment of pomalidomide either with or
without other pharmacological HbF inducers. The combination
of pomalidomide and decitabine had an additive effect on
induction, as shown by the differential HbF level (D%
HbF = 367  13) when compared to treatment with any sin-
gle agent (Fig 1A,B). Hydroxyurea did not generate any addi-
tional increase in HbF when combined with pomalidomide. The
Fig 1. Robust HbF induction in b0-thalassaemia/HbE erythroid cells by pomalidomide alone or in combination with other HbF inducers. b0-Tha-
lassaemia/HbE erythroblasts were treated with 40 lmol/l pomalidomide only (Pom, from day 4–14), 10 lmol/l hydroxyurea only (HU, from
day 8–14), 01 lmol/l decitabine only (DAC, from day 8–14), 002 lmol/l RN-1 only (from day 8–14), or in combination of Pom with HU, with
DAC, or with RN-1. (A) Representative high-performance liquid chromatograms (HPLC) showing haemoglobin composition at day 14 of ery-
throid differentiation. (B) The percentage of HbF relative to total Hb (%HbF + %HbE) determined by HPLC at day 14 of erythroid differentia-
tion. The increase in HbF percentage after treatment from the baseline level in dimethyl sulfoxide (DMSO) control was expressed as D%HbF (%
HbF [compound treatment] – %HbF [DMSO control]). Mean  standard error of the mean [SEM], n = 10 for HU, DAC and RN-1; n = 15 for
Pom, Pom + HU and Pom + DAC; and n = 13 for Pom + RN-1. (C) Quantitative reverse transcription polymerase chain reaction analysis show-
ing relative HBA, HBB and HBG mRNA expression levels normalised to b-actin (ACTB) at day 12 of erythroid differentiation. Data are presented
as the mean ( SEM) of relative fold change of DMSO (n = 5) *P < 005; **P < 0005; ***P < 00005; ****P < 00001.
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combination of pomalidomide and RN-1 did increase the per-
centage of HbF (Fig 1A,B) and at the same time reduced HBA,
HBB and HBG mRNA expression (Fig 1C), suggesting that this
combination negatively affected total globin mRNA expression.
Taken together, these results suggest that pomalidomide and
decitabine act through independent pathways to induce, addi-
tively, high-level HbF expression, implying a cooperative thera-
peutic potential for the treatment of b-thalassaemia.
We next determined the cytotoxicity of treatments and
found that pomalidomide did not significantly affect ery-
throid cell proliferation (Fig S5A) or viability (Fig S5B).
However, pomalidomide plus decitabine showed a reduction
in cell proliferation on day 12 of culture without affecting
cell viability. Erythroid cell proliferation and viability were
significantly reduced in cells exposed to pomalidomide plus
RN-1 (Fig S5A,B), suggesting toxicity of the latter combina-
tion. Analysis of erythroid differentiation of cells treated with
hydroxyurea or pomalidomide plus hydroxyurea was similar
to that of DMSO-treated cells (Fig 2A,B), suggesting that
these treatments did not affect erythroid terminal differentia-
tion. We noted a trend towards increased differentiation of
cells treated with pomalidomide, RN-1 and pomalidomide
plus RN-1, compared with the controls. Interestingly, signifi-
cantly accelerated erythroid differentiation was observed in
decitabine alone and pomalidomide plus decitabine, as evi-
denced by elevated transferrin receptor (CD71)medium/(gly-
cophorin A (GPA)high population and decreased CD71high/
GPAhigh cells (Fig 2A,B). Similarly, modified Giemsa-stained
cytospins showed an increased number of late-stage ery-
throblasts in cells exposed to decitabine alone and pomalido-
mide plus decitabine when compared to control cells,
indicating a shift towards normal erythroid cell maturation
(Fig 2C and Fig S1). These results suggested that the differ-
entiation of b0-thalassaemia/HbE progenitor cells signifi-
cantly improved after treatment with either decitabine alone
or pomalidomide plus decitabine.
To investigate the effects of pomalidomide plus or minus
these effectors on transcriptional regulation in b-thalassaemic
erythroid progenitor cells, quantitative RT-PCR analyses
revealed that one key c-globin repressor mRNA, BCL11A, was
only slightly reduced after treatment with pomalidomide or
pomalidomide plus hydroxyurea. BCL11A was significantly
downregulated (by 18- and 56-fold) after treatment with
pomalidomide plus decitabine or pomalidomide plus RN-1
respectively (Fig 2D). Moreover, the expression of SOX6,
GATA1, HBS1L and LRF were modestly but significantly
downregulated by pomalidomide, whereas other erythroid
regulators were unaffected (Fig 2D and Fig S6). In addition,
combined pomalidomide and decitabine treatment, which
showed additive effects on HbF induction, reduced the expres-
sion of KLF1, LSD1 and CHD4. The combination of poma-
lidomide plus RN-1 significantly affected the expression of
several key regulators, including KLF1, SOX6, GATA1, HBS1L,
DNMT1, LSD1, ID2, CHD4, FOXO3, NRF2 and MYB (Fig 2D
and Fig S6), consistent with the fact that this same combina-
tion significantly reduced cell proliferation and viability (Fig
S5). Taken together, these results indicate that the mecha-
nisms of action of pomalidomide and several co-effectors in
induction of HbF expression partly involve transcriptional
regulation of key HbF repressors and/or co-repressors.
In summary, the present data show that pomalidomide is
a potent HbF inducer and is more potent than hydroxyurea.
The combination of pomalidomide and decitabine provide
additive effects in inducing HbF expression in erythroid cells
from b0-thalassaemia/HbE patients. Despite these promising
results, it must be emphasized that the potential risks associ-
ated with the use of pomalidomide include developmental
defects (if taken during pregnancy), thrombosis and pancy-
topenia,17 which are similar to the toxicities of the parental
drugs, lenalidomide and thalidomide. Development of poma-
lidomide structural refinements or analogues with similar
biological effects may lead to future, fully effective, reduced
adverse effects and possible clinical application.
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Fig 2. Effect of pomalidomide and its combinations on erythroid differentiation and mRNA expression of HbF regulators in cultured erythroid
cells from b0-thalassaemia/HbE patients. b0-Thalassaemia/HbE erythroblasts were treated with 40 lmol/l pomalidomide only (Pom, from day 4
–14), 10 lmol/l hydroxyurea only (HU, from day 8–14), 01 lmol/l decitabine only (DAC, from day 8– 14), 002 lmol/l RN-1 only (from day
8–14), the combination of Pom with HU, with DAC, or with RN-1. (A) Representative flow cytometry dot plots for erythroid differentiation
analysis on day 12 of culture. Erythroid cells were gated into R1 to R4 populations according to the expression levels of transferrin receptor
(CD71) and glycophorin A (GPA/CD235a). (B) The histogram represents the quantitation of erythroid subpopulations analysed by flow cytome-
try. (mean  SEM, n = 3). *P < 005; **P < 0005, relative to dimethyl sulfoxide (DMSO) control. (C) Representative modified Giemsa-stained
cytospins at day 12 of culture showing erythroid morphology after DMSO or compound treatments. Scale bar = 10 lm. (D) Relative mRNA
abundance of known HbF regulators normalized to b-actin (ACTB) determined by quantitative reverse transcription polymerase chain reaction at
day 12 of erythroid cell culture. Gene names are shown at the top of each histogram. Data are presented as the mean ( SEM) of relative fold
change of DMSO . (n = 5) *P < 005; **P < 0005; ****P < 00001.
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Data S1. Supplemental methods.
Fig S1. Delayed erythroid differentiation is observed in b0-
thalassaemia/HbE comparing to normal erythroblast culture.
Fig S2. Time- and dose-dependent inducing effects of
pomalidomide on HbF induction in erythroid cells from b0-
thalassaemia/HbE patients.
Fig S3. HbF-inducing effects of hydroxyurea (HU), decita-
bine (DAC), and RN-1 in erythroid cells from b0-thalas-
saemia/HbE patients.
Fig S4. Pomalidomide and its combinations increase ery-
throid cells expressing HbF (F-cells).
Fig S5. Effect of pomalidomide and its combinations on
cell proliferation, viability of cultured erythroid cells from
b0-thalassaemia/HbE patients.
Fig S6. Treatment of pomalidomide and its combinations
alter the expression of HbF regulators in b0-thalassaemia/
HbE erythroid cells.
Table SI Haematological parameters of b0-thalassaemia/
HbE patients participated in this study.
Table SII Induction of HbF in erythroid progenitor cells
from b0-thalassaemia/HbE after treatments with poma-
lidomide, hydroxyurea, decitabine, RN-1 and their combi-
nations.
Table SIII Primers used in this study.
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Clinical and biological correlates of the expression of select
Polycomb complex genes in Brazilian children with acute
promyelocytic leukaemia
De novo acute promyelocytic leukaemia (APL) is an aggres-
sive subtype that accounts for 5–10% of all childhood acute
myeloid leukaemia (AML). In some Latin American and
European populations, APL is more frequent than in other
geographic populations. Approximately 97% of patients with
APL present t(15;17)(q22;q21.1)/promyelocytic leukaemia
(PML)-retinoic acid receptor alpha (RARA) fusion protein
and nearly all of the affected patients respond to therapy
with all-trans retinoic acid (ATRA) combined with arsenic
trioxide (ATO).1 Additionally, studies in transgenic mice
revealed that this transcript is necessary, but not sufficient,
for APL development, suggesting that additional genetic or
epigenetic changes are also required for the APL establish-
ment.2
The FMS-like tyrosine kinase 3-internal tandem duplica-
tion (FLT3-ITD) has been frequently reported in patients
with APL presenting a more aggressive disease course, with
lower overall and disease-free survival rates. These mutations
are known to co-operate with other initiating events to
advance disease progression, but they do not initiate leukae-
mia independently.3 Regarding paediatric APL, genomic
studies reported that APL cells have fewer genetic alterations
than those from other AML subtypes.4 These data indicate
that childhood APL development may require more than just
genetic alterations to manifest the disease phenotype.
In this context, there are several reports on the epigenetic
alterations implicated in AML development, and they are
mainly presented in APL. For instance, patients with APL are
characterised by a specific DNA methylation pattern, which
may be due to relatively late events in APL leukaemogenesis,
contributing to APL maintenance rather than leukaemia ini-
tiation.5
Besides, PML/RARA induces a multitude of alterations in
chromatin architecture, including the recruitment of crucial
epigenetic-modifying factors, such as histone deacetylase
complexes and DNA methyltransferases. Moreover, pieces of
evidence have revealed that the Polycomb repressor complex
(PRC) could contribute to the alterations observed in the
typical APL epigenetic landscape.6
Polycomb group (PcG) proteins are histone modifiers in
two multiprotein complexes: Polycomb repressive complexes
1 and 2 (PRC1 and PRC2). Radulovic et al.6 highlighted the
emerging implications of these genes in haematopoietic neo-
plasms, including myeloid neoplasia. Therefore, changes in
the expression profile of individual PcG genes might yield
novel information about APL pathogenesis.
We evaluated the PcG gene levels, namely, enhancer of
zeste homologue 2 (EZH2), Yin and Yang 1 protein (YY1),
BMI1 proto-oncogene, Polycomb ring finger (BMI1) and
suppressor of zeste 12 protein homologue (SUZ12), in a
cohort of 25 Brazilian children with APL, with and without
a FLT3-ITD mutation. In addition, we compared them to
those found in patients with other AML subtypes, with
and without the FLT3 mutation, to verify whether this
mutation status could be associated with the APL epige-
netic landscape.
Amongst the 25 patients with APL, eight had additional
chromosome abnormalities that mostly involved chromo-
somes 6, 8, 20 and 21. In the AML group, 39 patients had
their karyotype evaluated and the abnormalities detected
were as follows: 15 (385%) presented with lysine methyl-
transferase 2A (KMT2A) gene abnormalities; eight (205%)
presented with non-recurrent chromosome abnormalities;
four (103%) presented with RUNX1 translocation partner 1
(RUNX1)/RUNXT1 fusion genes; four (103%) presented
with core binding factor subunit beta (CBFB)/myosin heavy
chain 11 (MYH11) fusion genes; four (103%) presented with
normal karyotypes; three (77%) presented with abnormali-
ties in chromosomes 5 and 7; and one (24%) presented with
no mitosis. In relation to FLT3 status, 21 (309%) patients
had FLT3-ITD mutations, 13 (619%) were patients with
APL and eight (381%) were patients with AML [AML-M5
(five patients), AML-M2 (two) and AML-M6 (one)] (Clinical
data are in Table S1).
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